Market Cap | 4.13B | P/E | - | EPS this Y | -24.30% | Ern Qtrly Grth | - |
Income | -70.79M | Forward P/E | 20.08 | EPS next Y | 31.40% | 50D Avg Chg | -5.00% |
Sales | 2.3B | PEG | 2.10 | EPS past 5Y | -5.35% | 200D Avg Chg | - |
Dividend | N/A | Price/Book | 1.96 | EPS next 5Y | 16.00% | 52W High Chg | -19.00% |
Recommedations | 2.20 | Quick Ratio | 0.94 | Shares Outstanding | 24.43M | 52W Low Chg | 33.00% |
Insider Own | 7.86% | ROA | 0.56% | Shares Float | 22.50M | Beta | 0.65 |
Inst Own | 98.31% | ROE | -3.41% | Shares Shorted/Prior | 831.12K/1.39M | Price | 171.50 |
Gross Margin | 32.47% | Profit Margin | -3.07% | Avg. Volume | 179,493 | Target Price | 162.00 |
Oper. Margin | 4.11% | Earnings Date | Nov 4 | Volume | 157,604 | Change | -1.83% |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Raymond James | Outperform | Sep 12, 24 |
Keybanc | Overweight | Aug 8, 24 |
Raymond James | Outperform | Aug 8, 24 |
Needham | Hold | Aug 8, 24 |
Needham | Hold | Jun 21, 24 |
Raymond James | Outperform | Jun 17, 24 |
Keybanc | Overweight | Feb 28, 24 |
Keybanc | Overweight | Feb 6, 24 |
CL King | Buy | Dec 14, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Woolson Daniel | VP, GM-Infusion Capi.. VP, GM-Infusion Capital | Dec 01 | Sell | 88.0256 | 1,729 | 152,196 | 9,877 | 12/01/23 |
Voigtlander Christian B. | Chief Operating Offi.. Chief Operating Officer | Sep 08 | Sell | 129.31 | 6,850 | 885,774 | 13,603 | 09/11/23 |
Jain Vivek | Chairman and CEO Chairman and CEO | Jul 12 | Sell | 180.02 | 30,000 | 5,400,600 | 23,677 | 07/14/23 |
Jain Vivek | Chairman and CEO Chairman and CEO | Jul 12 | Option | 58.79 | 30,000 | 1,763,700 | 53,677 | 07/14/23 |
Jain Vivek | Chairman and CEO Chairman and CEO | Jun 14 | Sell | 190.21 | 30,000 | 5,706,300 | 23,677 | 06/15/23 |
Jain Vivek | Chairman and CEO Chairman and CEO | Jun 14 | Option | 58.79 | 30,000 | 1,763,700 | 25,881 | 06/15/23 |
KENNEDY KOLLEEN T | Director Director | May 17 | Option | 0.00 | 485 | 614 | 05/18/23 | |
Hoffmeister David F | Director Director | May 17 | Option | 0.00 | 485 | 2,079 | 05/18/23 | |
FINNEY ELISHA W | Director Director | May 17 | Option | 0.00 | 485 | 1,675 | 05/18/23 | |
Abbey Donald | Director Director | May 17 | Option | 0.00 | 485 | 2,079 | 05/18/23 | |
Hernandez Laurie | Director Director | May 17 | Option | 0.0 | 485 | 937 | 05/18/23 | |
Greenberg David C. | Director Director | May 17 | Option | 0.0 | 485 | 4,089 | 05/18/23 | |
Sanzone Virginia Ruth | VP, General Counsel VP, General Counsel | Apr 11 | Sell | 175.0 | 250 | 43,750 | 4,678 | 04/11/23 |
Sanzone Virginia Ruth | VP, General Counsel VP, General Counsel | Apr 05 | Sell | 170.0 | 458 | 77,860 | 4,928 | 04/05/23 |
LOPEZ GEORGE A | Director Director | Sep 21 | Option | 61.76 | 79,576 | 4,914,614 | 361,020 | 09/21/22 |
Sanzone Virginia Ruth | VP, General Counsel VP, General Counsel | May 12 | Sell | 173.56 | 750 | 130,170 | 3,371 | 05/12/22 |
Hernandez Laurie | Director Director | May 11 | Option | 0.0 | 352 | 452 | 05/12/22 | |
Greenberg David C. | Director Director | May 11 | Option | 0.0 | 433 | 3,604 | 05/12/22 | |
Jain Vivek | Chairman and CEO Chairman and CEO | Mar 03 | Option | 58.79 | 36,000 | 2,116,440 | 48,779 | 03/04/22 |
Jain Vivek | Chairman and CEO Chairman and CEO | Mar 03 | Sell | 240 | 36,000 | 8,640,000 | 12,779 | 03/04/22 |
FINNEY ELISHA W | Director Director | Sep 14 | Sell | 242.2 | 2,424 | 587,093 | 1,717 | 09/14/21 |
FINNEY ELISHA W | Director Director | Sep 14 | Option | 101.06 | 2,424 | 244,969 | 4,141 | 09/14/21 |
Sanzone Virginia Ruth | VP, General Counsel VP, General Counsel | Sep 13 | Sell | 251.44 | 800 | 201,152 | 1,605 | 09/13/21 |
SWINNEY ROBERT S | Director Director | Jun 03 | Option | 41.5 | 3,000 | 124,500 | 27,473 | 06/03/21 |
SWINNEY ROBERT S | Director Director | Jun 03 | Sell | 203.26 | 4,500 | 914,670 | 22,973 | 06/03/21 |
LOPEZ GEORGE A | Director Director | Apr 16 | Sell | 209.44 | 25,000 | 5,236,000 | 911,843 | 04/16/21 |
LOPEZ GEORGE A | Director Director | Apr 12 | Sell | 204.66 | 25,000 | 5,116,500 | 936,843 | 04/12/21 |
Jain Vivek | Chairman and CEO Chairman and CEO | Jan 08 | Option | 58.79 | 69,000 | 4,056,510 | 104,832 | 01/08/21 |
Jain Vivek | Chairman and CEO Chairman and CEO | Jan 08 | Sell | 220 | 69,000 | 15,180,000 | 66,241 | 01/08/21 |
Jain Vivek | Chairman and CEO Chairman and CEO | Dec 07 | Option | 58.79 | 11,500 | 676,085 | 75,441 | 12/07/20 |
Jain Vivek | Chairman and CEO Chairman and CEO | Dec 07 | Sell | 195 | 11,500 | 2,242,500 | 66,241 | 12/07/20 |
Jain Vivek | Chairman and CEO Chairman and CEO | Nov 10 | Option | 58.79 | 11,500 | 676,085 | 77,741 | 11/10/20 |
Jain Vivek | Chairman and CEO Chairman and CEO | Nov 10 | Sell | 195 | 11,500 | 2,242,500 | 66,241 | 11/10/20 |